Bruno Francesco, Pellerino Alessia, Palmiero Rosa, Bertero Luca, Mantovani Cristina, Garbossa Diego, Soffietti Riccardo, Rudà Roberta
Division of Neuro-Oncology, Department of Neuroscience, University and City of Health and Science, 10126 Turin, Italy.
Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Biomedicines. 2022 Mar 10;10(3):644. doi: 10.3390/biomedicines10030644.
Glioblastoma (GBM) is the most aggressive primary brain tumour. As GBM incidence is associated with age, elderly people represent a consistent subgroup of patients. Elderly people with GBM show dismal prognosis (about 6 months) and limited response to treatments. Age is a negative prognostic factor, which correlates with clinical frailty, poorer tolerability to surgery or adjuvant radio-chemotherapy, and higher occurrence of comorbidities and/or secondary complications. The aim of this paper is to review the clinical and molecular characteristics, current therapeutic options, and prognostic factors of elderly patients with GBM.
胶质母细胞瘤（GBM）是最具侵袭性的原发性脑肿瘤。由于GBM的发病率与年龄相关，老年人是一个稳定的患者亚组。患有GBM的老年人预后不佳（约6个月），对治疗的反应有限。年龄是一个负面的预后因素，它与临床虚弱、对手术或辅助放化疗的耐受性较差以及合并症和/或继发性并发症的发生率较高相关。本文的目的是综述老年GBM患者的临床和分子特征、当前的治疗选择以及预后因素。
